Effects of Chinese herbal medicine Yiqi Huaju Formula on hypertensive patients with metabolic syndrome: a randomized, placebo-controlled trial

被引:38
作者
Chen, Yi [1 ]
Fu, De-yu [2 ]
Chen, Yu [2 ,3 ]
He, Yan-ming [2 ]
Fu, Xiao-dong [1 ]
Xu, Yan-qiu [2 ]
Liu, Yi [1 ]
Feng, Xiao-tao [1 ]
Zhang, Teng [2 ,3 ]
Wang, Wen-jian [1 ,3 ]
机构
[1] Fudan Univ, Huashan Hosp, Inst Integrat Med, Shanghai 200040, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Clin Res Inst Integrat Med, Shanghai 200437, Peoples R China
来源
JOURNAL OF INTEGRATIVE MEDICINE-JIM | 2013年 / 11卷 / 03期
关键词
metabolic syndrome; hypertension; ambulatory blood pressure monitoring; blood pressure variability; drugs; Chinese herbal; therapies; investigational;
D O I
10.3736/jintegrmed2013031
中图分类号
R [医药、卫生];
学科分类号
10 [医学];
摘要
BACKGROUND: Patients with hypertension coupled with metabolic syndrome (MetS) are among the high risk population in cardiovascular and cerebrovascular diseases. To reduce the prevalence of cardiovascular and cerebrovascular diseases, it is essential to appropriately control blood pressure together with other cardiovascular risk factors. OBJECTIVE: The current study was designed to investigate the therapeutic effects on blood pressure, blood pressure variability and other cardiovascular risk factors by giving Yiqi Huaju Formula, a compound traditional Chinese herbal medicine, in addition to routine treatment to hypertensive patients coupled with MetS. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 43 patients with hypertension coupled with MetS were recruited into this study. The enrolled patients were randomly divided into the Chinese herbal formula group (anti-hypertensive drugs plus Yiqi Huaju Formula, CHF) and the control group (anti-hypertensive drugs plus placebo). The CHF group enrolled 22 patients while the control group received 21 cases. Treatments were given for 12 weeks in both groups. MAIN OUTCOME MEASURES: Parameters examined include 24-hour ambulatory blood pressure monitoring, body mass index, waist circumference, waist-to-hip ratio, homeostatic model assessment for insulin resistance (HOMA-IR), fasting glycosylated hemoglobin (HbA1c), fasting plasma glucose, 2-hour postprandial plasma glucose (PPG), fasting plasma insulin, serum lipid, etc. RESULTS: Compared with the control group, the CHF group had significant improvement (P<0.01) in anthropometric parameters, FPG, HOMA-IR, blood pressure amplitude, blood pressure variability and blood pressure load. CONCLUSION: This study showed that integrated traditional Chinese and Western medicine treatment can achieve better results in controlling blood pressure as well as other cardiovascular risk factors. The mechanism of controlling of blood pressure may be associated with the improvement of insulin sensitivity due to the Yiqi Huaju intervention.
引用
收藏
页码:184 / 194
页数:11
相关论文
共 36 条
[1]
Aalbers J, 2010, CARDIOVASC J AFR, V21, P53
[2]
Diuretic versus α-blocker as first-step antihypertensive therapy -: Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [J].
Alderman, MH .
HYPERTENSION, 2003, 42 (03) :239-246
[3]
Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population [J].
Andreadis, Emmanuel A. ;
Tsourous, George I. ;
Tzavara, Chara K. ;
Georgiopoulos, Dimitrios X. ;
Katsanou, Panagiota M. ;
Marakomichelakis, George E. ;
Diamantopoulos, Emmanuel J. .
AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (05) :558-564
[4]
Anonymous, 2007, Zhonghua Xinxueguanbing Zazhi, V35, P390
[5]
Optimizing management of metabolic syndrome to reduce risk: focus on life-style [J].
Bianchi, Cristina ;
Penno, Giuseppe ;
Daniele, Giuseppe ;
Benzi, Luca ;
Del Prato, Stefano ;
Miccoli, Roberto .
INTERNAL AND EMERGENCY MEDICINE, 2008, 3 (02) :87-98
[6]
Chen Yi, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P1114, DOI 10.3736/jcim20101202
[7]
Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong cardiovascular risk factor prevalence study-2 (CRISPS2) [J].
Cheung, Bernard M. Y. ;
Wat, Nelson M. S. ;
Man, Y. B. ;
Tam, Sidney ;
Cheng, C. H. ;
Leung, Gabriel M. ;
Woo, Jean ;
Janus, Edward D. ;
Lau, C. P. ;
Lam, T. H. ;
Lam, Karen S. L. .
AMERICAN JOURNAL OF HYPERTENSION, 2008, 21 (01) :17-22
[8]
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[9]
CLEMENT DL, 1994, J HYPERTENS, V12, pS49
[10]
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906